Definitive Healthcare CORP 8-K filings

Definitive Healthcare Corp. has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Definitive Healthcare Corp. and SE VII DHC AIV, L.P. (Spectrum) have terminated their Nominating Agreement, ending Spectrum's right to designate a board nominee.

Definitive Healthcare Corp. announced fourth quarter and full year 2025 financial results, with Q4 revenue exceeding guidance despite a year-over-year decrease.

Definitive Healthcare reported Q3 2025 financial results, with revenue at the high end of guidance and Adjusted EBITDA exceeding expectations, despite a year-over-year revenue decrease.

Definitive Healthcare reported second-quarter revenue of $60.8 million, exceeding guidance, and raised its full-year 2025 revenue and adjusted EBITDA outlook despite year-over-year declines in key financial metrics.

Definitive Healthcare Corp. reports the resignation of Jill Larsen from its Board of Directors and Compensation Committee, leading to a reduction in board size and the appointment of Scott Stephenson as the new Compensation Committee Chair.

Definitive Healthcare Corp. announced the elimination of its Chief Operating Officer position, leading to the departure of Kate Shamsuddin Jensen as part of an executive leadership reorganization.

Definitive Healthcare Corp. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all proposals, including the election of Class I directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation, were passed.

Definitive Healthcare announced its Q1 2025 financial results, with revenue exceeding guidance but showing a decrease compared to the previous year, alongside a significant net loss due to goodwill impairment charges.

Definitive Healthcare announced the appointment of Casey Heller as CFO effective June 2, 2025, alongside its Q4 and full year 2024 financial results, which showed a revenue decrease in Q4 but overall growth for the year.

Definitive Healthcare Corp. secures a new credit agreement amendment, refinancing existing debt with a $175 million term loan and a $50 million revolving credit facility.

Definitive Healthcare reported third-quarter results exceeding revenue guidance, authorized a $100 million stock repurchase program, and announced the upcoming departure of its CFO.

Definitive Healthcare Corp. has promoted Kate Shamsuddin Jensen to Chief Operating Officer, effective October 1, 2024.

Definitive Healthcare's second quarter saw a 5% revenue increase year-over-year, but a significant net loss due to a $363.6 million goodwill impairment charge.

Definitive Healthcare Corp. reported preliminary second-quarter results including a significant goodwill impairment charge and revised its full-year financial guidance.

Definitive Healthcare Corp. has officially appointed Kevin Coop as CEO, effective June 24, 2024, and granted him a significant equity award to compensate for prior share price volatility.

Definitive Healthcare Corp. has appointed Kevin Coop as its new CEO, effective June 24, 2024, and granted him significant equity incentives.

Definitive Healthcare announced a 7% year-over-year revenue increase to $63.5 million for Q1 2024, alongside a net loss of $12.7 million, but highlighted a strong adjusted EBITDA margin of 32%.

Definitive Healthcare announced a 9% year-over-year revenue increase for the fourth quarter of 2023 and a 13% increase for the full year, alongside a significant net loss, while providing financial guidance for 2024.

Definitive Healthcare announced the departure of its CEO, Robert Musslewhite, and the appointment of founder Jason Krantz as interim CEO, while reaffirming its Q4 2023 guidance and issuing preliminary 2024 guidance.